Ramana Moorthy, MD
Retina Specialist · Carmel, INNPI 1902800493
Payments from drug & device makers
Across 143 payments — averaging $2643.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ocular Therapeutix, Inc.$287K
- US Retina LLC$58K
- Boehringer Ingelheim International GmbH$30K
- Coherus Oncology, Inc.$2K
- Eyepoint US, Inc.$285
- Bausch & Lomb Americas Inc.$272
- plus $1K from 15 others
Across 1 payment — averaging $9600.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ocular Therapeutix, Inc.$10K
What the payments were for
- Consulting fees$1,3502%
- Food & beverage$1,9143%
- Ownership interest$24,97541%
- Other$33,25954%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ocular Therapeutix, Inc. | 57 | $286,730 |
| US Retina LLC | 11 | $58,234 |
| Boehringer Ingelheim International GmbH | 25 | $29,771 |
| Coherus Oncology, Inc. | 4 | $1,524 |
| Eyepoint US, Inc. | 6 | $285 |
| Bausch & Lomb Americas Inc. | 2 | $272 |
| Regeneron Healthcare Solutions, Inc. | 8 | $219 |
| Genentech USA, Inc. | 8 | $178 |
| Astellas Pharma US Inc | 4 | $158 |
| Alimera Sciences, Inc. | 3 | $128 |
| Alcon | 2 | $126 |
| Novartis | 2 | $103 |
| Regeneron | 1 | $73 |
| Apellis Pharmaceuticals, Inc. | 3 | $57 |
| Amgen | 1 | $22 |
| Sun Pharmaceutical Industries Inc. | 1 | $17 |
| Biogen | 1 | $16 |
| Bioptics, Inc. | 1 | $15 |
| AbbVie | 1 | $14 |
| Spark Therapeutics, Inc. | 1 | $14 |
| Kala Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$377,969 in reported general payments places this provider in the 80th percentile of 21 retina specialist providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 18 | $195,201 |
| Prednisolone Acetate | 343 | $16,232 |
| Difluprednate | 100 | $11,489 |
| Mycophenolate Mofetil | 83 | $10,823 |
| Fluorometholone | 72 | $5,592 |
| MoxifloxacinMoxifloxacin Hcl | 142 | $4,182 |
| ValacyclovirValacyclovir Hcl | 58 | $3,908 |
| Loteprednol Etabonate | 17 | $2,984 |
| Ketorolac Tromethamine | 133 | $2,832 |
| Bromfenac Sodium | 19 | $2,810 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 31 | $2,038 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 90 | $1,410 |
| Prednisone | 133 | $898 |
| Atropine Sulfate | 22 | $742 |
| Acetazolamide ErAcetazolamide | 16 | $711 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Carmel
- Raj MaturiCarmel$3.3M
- Ankur ShahCarmel$2M
- Milan ShahCarmel$802K
- Rodney BucherCarmel$30K
- Stephen SaxeCarmel$14K
- Denis JusufbegovicCarmel$8K
- Mark KaehrCarmel$5K
- Julia HudsonCarmel$3K
- Frederick PrallCarmel$475
- John MinturnCarmel$133
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.